Drug Search Results
More Filters [+]

CKD-396

Alternative Names: ckd-396, ckd 396, ckd396
Latest Update: 2020-02-05
Latest Update Note: Clinical Trial Update

Product Description

CKD-396 is being developed by Chong Kun Dang for the treatment of patients with Type2 Diabetes Mellitus. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04246190?term=CKD-396&draw=2&rank=1)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chong Kun Dang
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CKD-396

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A65_03BE1921

P1

Unknown status

Type 2 Diabetes

2020-04-10

59%

Recent News Events

Date

Type

Title